Rare disease drug developer Ultragenyx Pharmaceutical Inc. is expected to hit the market next week — the first of a new wave of biotech initial public offerings — with an IPO that could raise nearly $95 million. The Novato company, founded by former BioMarin Pharmaceutical Inc. chief medical officer Emil Kakkis, last week priced 4.8 million shares in its IPO at $14 to $17 per share. Ultragenyx, which would trade on the NASDAQ exchange as “RARE,” has four drugs in clinical trials.
Help employers find you! Check out all the jobs and post your resume.
